Funding Support for Dr. Meltzer-Brody

- NIH K23 Mentored Career Development Award
- AstraZeneca
- Foundation of Hope
What reproductive mental health issues specific to women are encountered by health workers?

- Premenstrual Dysphoric Disorder
- Perinatal Psychiatry
- Perimenopause
Mood Disorders in Women in the General Population

- Depressive disorders are very common
- Lifetime prevalence rates range from 4.9% - 17.1%
- Women report a history of major depression at nearly twice the rate of men
- Depression is now considered the leading cause of disease-related disability among women in the world
- Women of childbearing age are at high risk for major depression

DSM-IV Criteria for Major Depression

Five (or more) of nine symptoms:

- Depressed mood
- Loss of interest or pleasure in almost all activities
- Significant weight loss or weight gain
- Insomnia or hypersomnia
- Restlessness or feeling slowed down
- Fatigue
- Worthlessness or inappropriate guilt
- Inability to concentrate
- Suicidal ideation
DSM-IV Criteria for Major Depression (MDD)

- Must be present during the same 2-week period
- Represents a change from previous functioning
- At least one of the symptoms is either
  1) depressed mood or
  2) loss of interest or pleasure
PMS & Premenstrual Dysphoric Disorder

- PMS is common—estimated prevalence is 3% - 10% of general population
- PMDD is less common, prevalence rate of 2% - 5%
Menstrual Related Mood Disorders

- Premenstrual Syndrome (PMS):
  - Constellation of emotional & physical symptoms
  - Occurs during luteal phase (post ovulation)

- Premenstrual Dysphoric Disorder (PMDD)
  - Symptoms must be present during most menstrual cycles
  - Occurs during luteal phase
  - DMS-IV Symptoms include:
    - Depressed mood
    - Marked anxiety & affective lability
    - Marked anger, irritability or interpersonal conflicts
    - Other neurovegetative symptoms of depression
Assessment of Premenstrual Complaints

- Assess the reproductive endocrine status
- Rule out underlying medical conditions
- Rule out underlying psychiatric conditions
- Perform **prospective** daily rating scales
Treatment of PMDD

- **Non-pharmacologic**
  - Calcium supplements (1000mg/day)
  - Magnesium supplements (360mg/day)
  - Aerobic exercise
  - CBT, relaxation
  - Circadian rhythm manipulations

- **Hormonal**
  - Oral Contraceptive Pills

- **Psychotropic Medications**
Psychotropic Treatment of PMDD

- Selective Serotonin Reuptake Inhibitors
  - Efficacy of SSRI treatment has been demonstrated in multiple studies with fluoxetine, sertraline and paroxetine
  - Luteal phase dosing vs. standing dosing

- Benzodiazepines

- Other agents
Menopause

- No specific psychiatric disorder has been associated with menopause itself.

- However, the relationship between declining estrogen levels and mood symptoms is controversial.

- Certain subgroups of women may be more vulnerable to developing psychiatric symptoms.
Etiology of Menopause

- Usually occurs naturally with advancing age, between 41-59 yrs
- Can be a direct result of surgical removal of ovaries
- Can result from hormone therapy
Perimenopause

- The “transition” or “change of life” from regular menstrual functioning to menopause
- Usually last 5-10 years
- Decreasing estrogen levels
- Unopposed progesterone
- Increased rate of depressive symptoms
There is evidence that “estrogen withdrawal” may play a role in the development of mood symptoms.

Women with a history of major depression may be at risk for perimenopausal depression.
Psychosocial Issues During Menopause

- Losing one’s reproductive functioning
- Changing family roles
- Onset of physical illness
- Aging
- Cultural stereotypes (empty nest) vs. positive feelings of maturity
Treatment of Mood Symptoms during Menopause

- “Usual Care” strategies for treating depressive disorders
  - Psychotherapy
  - Pharmacotherapy
  - Good Psychoeducation

- The ever-changing HRT controversy
  - Review current recommendations
Perinatal Mood Disorders: Etiology

- Caused primarily by changes in levels of estrogen and progesterone

- Life stressors, such as moving, illness, poor partner support, financial problems, and social isolation can negatively affect the woman’s mental state

- Strong emotional, social, and physical support can greatly facilitate her recovery
At childbirth and during the transition to the postpartum period the following occur:

- **Estrogen and progesterone** rapidly decline
- **There is blunted HPA axis activity** due to suppressed hypothalamic CRH secretion
- **These normal changes are altered in women** with PPD
Background: Perinatal Depression

COMMON

- 10% - 15% prevalence
- 4,000,000 women give birth annually in U.S., 500,000 with PPD
- Most common, unrecognized complication of perinatal period
- Compare to prevalence rate of gestational diabetes at 2% - 5%

Background: Perinatal Depression

MORBID

- Devastating consequences for patient and family
  - Low maternal weight gain, preterm birth
  - Impaired bonding between mother and infant
  - Increased risk of suicide and infanticide

MISSED

- No practice guidelines or routine screening
- Symptoms often different from “classic DSM-IV depression”

Mood Symptoms in the Perinatal Period

Distinguishing characteristics are:

- Anxiety or agitation
- Depressed mood
- Sadness, weepiness
- Irritability
- Lack of interest in the newborn
- Impaired concentration or feeling overwhelmed
- Feelings of dependency
Risk Factors for Perinatal Mood Symptoms

"Giving birth is like taking your lower lip and forcing it over your head.“  Carol Burnett

- Rapid hormonal changes
- Physical and emotional stress of birthing
- Physical discomforts
- Emotional letdown after pregnancy and/or birth
- Awareness and anxiety about increased responsibility
- Fatigue and sleep deprivation
- Disappointments including the birth, spousal support, nursing, and the baby
Postpartum Psychosis

- A rare but **devastating** condition, with an estimated prevalence of 0.1% - 0.2% (one to two per thousand)
  - Women with Bipolar Disorder, risk is 100 times higher at 10% - 20%
  - **Psychiatric emergency** & requires immediate treatment with a mood stabilizer & antipsychotic
- Onset usually 2-3 days postpartum
- Has a 5% suicide and 4% infanticide rate
- Risk for recurrent episode with subsequent pregnancy is 90%
Screening Instruments

- Edinburgh Postnatal Depression Scale (EPDS)
  - Most commonly employed screening tool
- Beck Depression Inventory (BDI)
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Hamilton rating Scale for Depression (HRSD)
- Nine Symptom Depression Checklist of the Patient Health Questionnaire (PHQ)
Edinburgh Postnatal Depression Scale (EPDS)

- Most commonly employed screening tool for PPD
- 10 questions self-rated instrument
- Validated and developed specifically to identify women experiencing postnatal depression
- English and Spanish versions
- Please see handout of complete screening tool
Treatment of PPD

- Critical for the well being of the woman, baby and family
- Effective treatments are readily available
- Skilled assessment and treatment by mental health professionals in perinatal psychiatry makes a difference in outcomes!!
Treatment must include both psychological and/or biological interventions

- Psychotherapy (individual and/or group)
- Increased social supports
- Exercise, good nutrition, adequate sleep
- Antidepressant medications if appropriate
- Careful monitoring
High risk of depressive relapse following antidepressant discontinuation during pregnancy

- Of 201 women in the sample, 86 (43%) experienced a relapse of major depression during pregnancy.
- Women who discontinued medication relapsed more frequently (68% vs 26%) compared to women who maintained medication.
- Pregnancy is not "protective" with respect to risk of relapse of major depression.

Pharmacotherapy in Pregnancy

- All psychotropics cross the placenta and none are approved by the FDA for use during pregnancy.
- Unethical to conduct randomized placebo controlled studies on medication safety in pregnant women.
- Thus, most information about the reproductive safety of drugs comes from case reports and retrospective studies.
- Prevalence of SSRI use in pregnancy is 6% - 8%.
SSRI Use During Pregnancy

Important issues to consider:

- First trimester exposure
- Third trimester exposure and risk of “discontinuation syndrome”
- Must weigh risk/benefit ratio
  - Consider untreated or inadequately treated maternal depression vs. risk of antidepressant exposure
Neonatal Outcomes:

- SSRI withdrawal is possible but usually these are transient (restlessness, rigidity, tremor)
- Late SSRI exposure carries an overall risk ratio of 3.0 (95% CI, 2.0-4.4) for a neonatal behavioral syndrome
- Neonatal behavioral syndrome in 31.5% of infants in late-exposed group, 8.9% in early-exposure group for fluoxetine
Primary Pulmonary Hypertension of the Newborn

- In 2006, a case control study showed SSRI exposure after 20 weeks gestation increased risk (4-5x higher) of PPHN with absolute risk of <1%

- Recent studies show increased risk of PPHN with multiple other risk factors and absolute low risk with SSRI exposure
  - C-section, high maternal BMI, AA or Asian heritage
  - Study concluded that large BMI and C-section had greater risk than SSRI exposure
    (Hernandez-Diaz S, Van Marter L, Risk Factors for Persistent Pulmonary Hypertension of the Newborn, Pediatrics, 2007; Aug;120(2):e272-82.)
  - Swedish Medical Birth Register– 3rd trimester exposure showed increased risk of 2.4
    (Kallen B, Olausson PO, Maternal Use of Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn, Pharmacoepidemiology and Drug Safety, 2008; Aug;17(8):801-6.)
    (Andrade SE, McPhillips, Antidepressant Medication Use and Risk of Persistent Pulmonary Hypertension of the Newborn, Pharmacoepidemiology and Drug Safety, 2009; Mar;18(3):246-52.)
What to do?

- SSRIs (especially fluoxetine and sertraline) and TCAs relatively safe even during first trimester
- SSRIs (especially sertraline) and TCAs relatively safe in breast-feeding. (Risk of fluoxetine accumulation in breastmilk and TCA-induced seizures)
- Avoid Paroxetine (unless risk/benefit analysis dictates otherwise)
- Insufficient information about newer antidepressants (SNRI’s), and trazodone
- Bupropion: FDA risk category changed from B to C
Psychotherapy During Pregnancy

- Psychotherapy can be an important form of treatment of depression during pregnancy and the postpartum period.

- Good data available for use of Cognitive-Behavioral (CBT) and Interpersonal Psychotherapy during pregnancy.

- Requires weekly visits and motivation/compliance by the patient.
Pregnant Women with Bipolar Disorder

- Present a complex clinical challenge
- Goal is to minimize the risk to the fetus, while limiting the impact of the psychiatric illness on the mother and her family
- Decisions surrounding psychotropic use are difficult and associated with risks
Lithium vs. Anticonvulsants

**LITHIUM**
- Ebstein’s cardiac malformation
  - 0.05% risk vs. 0.1% base rate
- Neonatal hypothyroidism
- Diabetes Insipidus (rare)
- Polyhydramnios (rare)
- FDA Pregnancy Category D

**VALPROIC ACID**
- Spina bifida (1%-5% risk)
- Structural defects of the heart, limbs and face
- FDA Pregnancy Class D

**CARBAMAZEPINE**
- Spina bifida (1% risk)
- Structural defects of the face (dysmorphic facies)
- Secreted in breast milk
- FDA Pregnancy Category C
Newer Anticonvulsants

- Limited data is available with the “newer" agents such as gabapentin, lamotrigine, oxcarbazepine and topiramate
- Lamotrigine has good safety record to date. No increased risk of birth defects
- The benzodiazepines may have increased risk of cleft lip and palate (0.7%)
- All are secreted in breast milk
- FDA pregnancy class C
Antipsychotics

- Teratogenic risks are probably low with the traditional neuroleptics (Haloperidol is safest)
- There is inadequate information available to ascertain risk of newer atypical antipsychotics, although safety profile is promising to date
- Quetiapine has lowest transmission in breast milk (All are secreted in breast milk)
- FDA pregnancy class C (except for clozaril)
Risk-Benefit Assessment for Lactation

- The majority of women plan to breastfeed
- 5% - 17% of nursing women take medications
- Breastfeeding is beneficial for the infant
- All psychotropic medications studied to date are secreted in breast milk
- Untreated maternal mental illness has an adverse effect on mother-infant attachment and infant development
Lactation - Mood Stabilizers/ Antipsychotic Medications

- Lithium:
  - The AAP cautions against Lithium during lactation
  - Consistently found in high concentrations in breast milk (24%-72% of maternal serum levels)

- Valproic Acid and other Anticonvulsants
  - Until recently AAP states they are compatible with breastfeeding
  - Newer studies raise concerns with Valproic Acid
  - Lamotrigine appears safe to date

- Atypical Antipsychotics
  - Literature is sparse
  - Quetiapine appears to have a low transmission into breast milk (0.1% of maternal dose) and no adverse effects
Infant Monitoring

- Most centers lack the clinical laboratory assays to detect typical infant serum concentrations
- Infant serum concentrations are uninterpretable
- Routine infant serum monitoring is **not routinely** recommended:
  - Except in the child who has potential medication side effects
  - Small proportion of breastfeeding children may be metabolic outliers for a particular medication and accumulate it
Conclusions: Treatment

- Perinatal psychiatric illness requires immediate intervention
- Coordination of care between OB-GYN and trained mental health professionals is critical
- Antidepressant medications can be safely used during pregnancy and lactation - assess risk of untreated illness vs. greater risk of exposure
- Chronic mental illness must be treated during pregnancy to prevent severe PPD
- Patients with preexisting psychosis must be treated as a “high risk pregnancy” during and after delivery
Clinical and Research Program that provides assessment, treatment and support for women in the perinatal period

Collaboration of doctors, nurses, midwives, therapists, & social workers who provide services for in patient and out patient units

www.womensmooddisorders.org
Patient Resources

- Postpartum Support International
  www.postpartum.net

- “Down Came the Rain” by Brooke Shields

- “This Isn’t What I Expected: Overcoming Postpartum Depression” by Karen Kleiman & Valerie Raskin

- “Beyond the Blues” by Bennett & Indman
For More Information

Samantha Meltzer-Brody, M.D., M.P.H.
Susan Killenberg, M.D.
Christena Raines, RN, MSN, APRN-BC
919-966-9640

samantha_meltzer-brody@med.unc.edu
susan_killenberg@med.unc.edu
christena_raines@med.unc.edu

UNC Center for Women’s Mood Disorders